{"id":"anavex2-73","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4594269","moleculeType":"Small molecule","molecularWeight":"317.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug binds to and activates sigma-1 receptors, which are involved in cellular stress response and neuroprotection. This activation is thought to reduce neuroinflammation, promote neuronal survival, and restore cellular homeostasis in neurodegenerative conditions. The mechanism may also involve modulation of autophagy and mitochondrial function.","oneSentence":"ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:36.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Blarcamesine","title":"Blarcamesine","extract":"Blarcamesine is an experimental drug which is under development for the treatment of Alzheimer's disease and other indications."},"indications":{"approved":[{"name":"Alzheimer's disease"},{"name":"Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT04314934","phase":"PHASE2, PHASE3","title":"OLE of Phase 2b/3 Study ANAVEX2-73-AD-004","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-10-10","conditions":"Alzheimer Disease","enrollment":300},{"nctId":"NCT04304482","phase":"PHASE2, PHASE3","title":"ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2020-07-01","conditions":"Rett Syndrome","enrollment":92},{"nctId":"NCT04575259","phase":"PHASE2","title":"OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-10-10","conditions":"Parkinson Disease Dementia","enrollment":132},{"nctId":"NCT03790709","phase":"PHASE2, PHASE3","title":"ANAVEX2-73 for Treatment of Early Alzheimer's Disease","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2018-07-03","conditions":"Alzheimer Disease","enrollment":509},{"nctId":"NCT03941444","phase":"PHASE3","title":"ANAVEX2-73 Study in Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-05-06","conditions":"Rett Syndrome","enrollment":33},{"nctId":"NCT03758924","phase":"PHASE2","title":"Study of ANAVEX2-73 in Patients With Rett Syndrome","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2019-02-28","conditions":"Rett Syndrome","enrollment":31},{"nctId":"NCT02756858","phase":"PHASE2","title":"An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2016-03","conditions":"Alzheimer's Disease","enrollment":21},{"nctId":"NCT03774459","phase":"PHASE2","title":"ANAVEX2-73 Study in Parkinson's Disease Dementia","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2018-07-09","conditions":"Parkinsons Disease With Dementia","enrollment":132},{"nctId":"NCT02244541","phase":"PHASE2","title":"Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Anavex Life Sciences Corp.","startDate":"2014-12","conditions":"Alzheimer's Disease","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Blarcamesine"],"phase":"phase_3","status":"active","brandName":"ANAVEX2-73","genericName":"ANAVEX2-73","companyName":"Anavex Life Sciences Corp.","companyId":"anavex-life-sciences-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANAVEX2-73 is a sigma-1 receptor agonist that activates neuroprotective pathways to treat neurodegenerative diseases. Used for Alzheimer's disease, Parkinson's disease dementia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}